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Abstract
Background
Parkinson’s disease (PD) is characterised by well-known motor symptoms, whereas the
presence of cognitive non-motor symptoms, such as emotional disturbances, is still under-
estimated. One of the major problems in studying emotion deficits in PD is an atomising
approach that does not take into account different levels of emotion elaboration. Our study
addressed the question of whether people with PD exhibit difficulties in one or more specific
dimensions of emotion processing, investigating three different levels of analyses, that is,
recognition, representation, and regulation.
Methodology
Thirty-two consecutive medicated patients with PD and 25 healthy controls were enrolled in
the study. Participants performed a three-level analysis assessment of emotional process-
ing using quantitative standardised emotional tasks: the Ekman 60-Faces for emotion rec-
ognition, the full 36-item version of the Reading the Mind in the Eyes (RME) for emotion
representation, and the 20-item Toronto Alexithymia Scale (TAS-20) for emotion regulation.
Principal Findings
Regarding emotion recognition, patients obtained significantly worse scores than controls
in the total score of Ekman 60-Faces but not in any other basic emotions. For emotion repre-
sentation, patients obtained significantly worse scores than controls in the RME experimen-
tal score but no in the RME gender control task. Finally, on emotion regulation, PD and
controls did not perform differently at TAS-20 and no specific differences were found on
TAS-20 subscales. The PD impairments on emotion recognition and representation do not
correlate with dopamine therapy, disease severity, or with the duration of illness. These
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results are independent from other cognitive processes, such as global cognitive status and
executive function, or from psychiatric status, such as depression, anxiety or apathy.
Conclusions
These results may contribute to better understanding of the emotional problems that are
often seen in patients with PD and the measures used to test these problems, in particular
on the use of different versions of the RME task.
Introduction
Parkinson’s disease (PD) is a common neurodegenerative condition associated with the loss of
dopamine producing neurons in the pars compacta region of the substantia nigra [1]. Main
motor manifestations of PD include resting tremor, bradykinesia, stiffness (rigidity), soft voice,
micrographia, shuffling steps, and difficulties with balance. Although the motor symptoms are
well known, this condition is also associated with a spectrum of non-motor dysfunctions, such
as cognitive impairment (mainly memory and executive functions) and neuropsychiatric dis-
turbances (mainly depression, anxiety, apathy, and emotional dysregulation disturbances),
symptoms that can be just as disabling as motor dysfunctions [2].
One of the key dimensions recently investigated among the social cognitive processes
affected in PD is the ability to manage emotional information in order to understand and inter-
pret social situations properly [3–6]. Even though the studies are inconclusive on the definition
of the degree and selectivity of impairments, there is evidence pointing to the existence of emo-
tional disorders in three main domains: emotion recognition, emotion representations, and
emotion regulation. For example, patients with PD show specific deficits in the recognition of
emotional facial expression, in particular the disgust expression, frequently accompanied by
impairment in the recognition of fear facial expressions ([7], for a review). In addition, differ-
ent studies highlight specific impairment of emotion representation, such as those associated
with affective Theory of Mind (ToM), i.e., the ability to represent others’ affective mental states
such as belief about feelings ([6], for a review). Lastly, further studies showed reduced reactivity
to emotional stimuli (i.e., emotional blunting), and linked these deficits to the inability to iden-
tify and describe one’s feelings distinguishing between feelings and bodily sensations of emo-
tional arousal, clinically defined as alexithymia [8–10]. Although there appears to be some
convergence of results, several discrepancies regarding emotion processing in PD have been
described (e.g., [5, 11, 12]), and further studies are needed to clarify the emotional profile of
patients with PD.
One of the major problems in studying emotion deficits in a neurodegenerative population
is an atomising approach that does not take into account different levels of emotion elaboration
[13–15]. In addition, the terminology used by different authors in the domain of social cogni-
tive processes is sometimes confusing. For example, the lack of agreement around the defini-
tions of emotion perception and ToM has been recently described [16]. A useful model for
testing emotional deficits was proposed by Decety in the domain of human empathy [17].
According to this model empathy involves at least two main areas, each with different develop-
mental trajectories: emotion understanding, i.e., the ability to recognise and represent emo-
tions, and emotion regulation, i.e., the ability to control emotion, affect, and motivation. In line
with this proposal, in the present study we investigate emotion understanding–distinguishing
between emotion recognition and representation–, and emotion regulation. Whereas emotion
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recognition is regarded as a low-level perceptual process involved in the identification of emo-
tionally salient information in the environment, emotion representation concerns a ToM
higher-level reasoning process involved in the integration and inference of social information
(both emotional and intentional) [18–20]. In particular, according to this perspective basic
emotions are recognised cross-culturally and are situation-based while social emotions are
belief-based and depend on other people’s feelings or thoughts. In other words, the more com-
plex the emotion, the greater degree of ToM is required to decode it [16, 18].
In line with these considerations, a crucial question concerning emotion processing in PD is
whether emotional disorders can be specifically explained by a deficit in the identification of a
specific emotion (emotion recognition), in the attribution of a specific affective mental state
(emotion representation), or by a deficit in the management of one’s emotion (emotion regula-
tion). Although current studies have investigated single specific dimensions of emotional disor-
der in PD, no study has yet compared these different dimensions of emotional processing in
the same experimental framework. The present research investigates PD emotional processing
comparing the three different levels: emotion recognition, representation, and regulation.
Accordingly, we used three quantitative standardised emotional tasks to test emotional pro-
cessing: (1) the Ekman 60-Faces task to test the recognition of basic facial emotions [21]; (2)
the Reading the Mind in the Eyes (RME) test, an affective ToM task based on the implicit abil-
ity to represent the feelings of another person by observing only their eyes [22]; and (3) the
20-item Toronto Alexithymia Scale (TAS-20), a validated self-report scale assessing the three
emotion regulation facets, namely the difficulty in identifying feelings, difficulty in describing
feelings, and externally oriented thinking [23].
Materials and Methods
Ethics Statement
The study was approved by the San Giovanni Battista University Hospital’s ethics committee
and was conducted in accordance with the Declaration of Helsinki. All the participants gave
their written informed consent to participate in the study.
Participants
Thirty-two consecutive patients with PD under dopaminergic replacement therapy and 25
healthy controls (HC) with negative neurological and psychiatric history were enrolled in the
study. All patients had been referred consecutively to the Neurology Unit of the Turin Univer-
sity Hospital for their standard care visits. Inclusion criteria for the patients included a diagno-
sis of idiopathic Parkinson’s disease, undergoing dopaminergic pharmacological treatment,
and an age greater or equal to 40 years. Exclusion criteria for all subjects were the presence of
dementia or severe cognitive impairment (Mini Mental State Examination, MMSE 26), and
presence of other neurological or psychiatric disorders, such as severe depression. All patients
were scored on the Unified Parkinson’s Disease Rating Scale (UPDRS) I to IV [24] and Hoehn
and Yahr Staging Scale (H&Y) [25]. Depression severity was assessed using the Beck Depres-
sion Inventory (BDI) [26], a validated measure for depression symptoms in PD [27]. All
patients included in the study were administered their daily optimal dopamine replacement
therapy (Levodopa preparations, and/or dopamine receptor agonists). Patients were assessed
for neuropsychological and psychological profile in their usual optimal medication-on condi-
tion (MED ON).
Emotion Processing in Parkinson's Disease
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Neuropsychological and clinical assessment
The MMSE [28] and Frontal Assessment Battery (FAB) [29] were administered to all subjects
for a preliminary screening of global cognitive and executive functioning. Patients were given a
standardised neuropsychological test battery in order to assess reasoning, memory, and atten-
tional executive functions [30]. Visuospatial abilities and reasoning was evaluated by means of
the Attentional Matrices task [31] and the Raven Color Matrices (PM 47) [32]. Verbal and spa-
tial short-term memory was assessed by means of the bisyllabic word repetition test (BWR)
[31] and Corsi’s block-tapping test [31], respectively. The assessment of verbal learning was
achieved by means of the paired-associate learning (PAL) [33], a Wechsler Memory Scale sub-
test. Frontal lobe executive functions, including the development of abstract concepts and the
shift of attention and motor sets, were assessed by means of the Trail Making Test Part B [34]
and the Nelson Modified Card Sorting Test (MCST) [35], a modified version of the Wisconsin
Card Sorting Test. In addition, patients were given phonemic [36] and category verbal fluency
tasks [31]. The clinical assessment included the Apathy Evaluation Scale [37], State Trait Anxi-
ety Inventory (STAI) [38], in particular, (STAI-X1, state anxiety) and (STAI-X2, trait anxiety),
as well as BDI.
Emotional assessment
Patients with PD and HC performed a three-level analysis assessment of emotional processing
using quantitative standardised emotional tasks: the Ekman 60-Faces task for emotion recogni-
tion, the 36-item full version RME task for emotion representation, and the TAS-20 for emo-
tion regulation.
The Ekman 60-Faces task is a tool to test the recognition of basic facial emotions using pho-
tographs of the faces of 10 people (6 women), selected from Ekman and Friesen [21]. The Ital-
ian version of this task was used [39]. Each photograph displayed six facial expressions
corresponding to six emotions: anger, disgust, fear, sadness, happiness, and surprise, giving 60
photographs (10 for each emotion). Pictures were presented on a computer screen one at a
time in pseudo-random order and participants were asked to select one of six emotion labels
(anger, disgust, fear, sadness, happiness, surprise) that best described the facial expression
shown. No feedback was given as to the appropriateness of any response.
The 36-item full version of the RME task is an advanced affective ToM task involving pre-
sentation of photographs of the eye region of human faces, and is based on the ability to repre-
sent the feelings of another person by observing only their eyes [22]. Participants are required
to choose which word, among four options, best describes what the character in the photo-
graph is thinking or feeling (e.g., which of the following words best describes the eye region
shown: excited, relieved, shy, or despondent). Explanations of emotion labels, according to the
definitions provided by the Italian version of the task [40], were given to subjects when asked
by the subjects themselves. The total number of correct choices indicates the RME perfor-
mance. In addition to the RME, we administered the RME gender control task (identification
of the gender of the character in the photograph).
The 20-item Toronto Alexithymia Scale is an extensively validated self-report questionnaire
to assess emotion regulation [23, 41]. The scale comprises three subscales that investigate the
following factors: (F1) difficulty in identifying feelings (e.g., “I am often confused about what
emotion I am feeling”; “I have feelings that I cannot quite identify”); (F2) difficulty in describ-
ing and communicating feelings (e.g., “I find it hard to describe how I feel about people”; “It is
difficult for me to reveal my innermost feelings, even to close friends”); (F3) externally oriented
thinking (e.g., “I prefer to analyse problems rather than just describe them”; “I prefer talking to
people about their daily activities rather than their feelings”). The total score on the
Emotion Processing in Parkinson's Disease
PLOS ONE | DOI:10.1371/journal.pone.0131470 June 25, 2015 4 / 18
questionnaire allowed categorizing the subjects according to their alexithymic dimension: non-
alexithymic (score: 20–51), borderline alexithymic (score: 52–60), or alexithymic (score61).
The Italian version of this test was used [42].
Statistical analysis
The statistical analyses were carried out with SPSS version 21.0 for Windows. For normally dis-
tributed data, parametric tests were used (t-test for independent samples, and repeated-mea-
sures analysis of variance, ANOVA). In cases of significant deviations from the assumption of
normality of variables distribution, we used non-parametric methods (Mann–Whitney U-test),
as specified in the related tables. Besides, to investigate the correlations between variables in the
groups of participants, we ran bivariate Pearson’s correlations. The level of significance for all
statistical tests was set at p< 0.05.
Results
Demographic and preliminary clinical assessments
Table 1 shows the demographic, neuropsychological, and clinical data of PD and HC. Patients
with PD and HC were well matched for demographic variables such as age, education, and gen-
der. Regarding the neuropsychological measures, patients and HC did not differ in terms of
their MMSE score, whereas the two groups differed in the FAB scores; however, only two
patients obtained a FAB score below the cut-off of 15.
Emotional assessment
The difference in performance between patients with PD and HC for the TAS-20, RME, and
Ekman 60-Faces tests are presented in Table 2. Patients obtained significantly worse scores
than HC in the RME experimental score, and in the total score of Ekman 60-Faces test. For
comparisons on basic emotions between the two groups of participants (sadness, happiness,
anger, disgust, fear, surprise), we adopted a prudent and conservative approach by using Bon-
ferroni’s correction from multiple comparisons (α = 0.05/6 = 0.008). Accordingly, none of the
comparisons between the two groups reached statistical significance. Taking into account the
possible influence of the frontal measure FAB on these group comparisons, we repeated them
by considering the FAB score as a covariate, and no significant change emerged. Moreover, no
statistically significant differences were found between the two groups in the RME gender con-
trol task score and TAS-20 total score. In order to investigate the possible relationship between
emotional (TAS-20 total score, RME and Ekman 60-Faces) and psychiatric (BDI, STAI, and
Apathy Evaluation Scale) measures, we analysed bivariate correlations in the group of patients
with PD between all these variables, but did not find any statistically significant differences,
with the only exception of the significant correlation between TAS-20 total score and STAI-X2
(r = 0.387, p = 0.046).
Alexithymia total scores ranged from 34 to 70 in the PD group (median = 56.50) and from
24 to 76 in the HC group (median = 50). Based on the TAS-20 score, 9 patients with PD (30%)
and 7 HC (28%) could be classified as alexithymic; 13 patients with PD (43.33%) and 13 HC
(52%) were non-alexithymic, and the remaining 8 patients with PD (26.67%) and 5 HC (20%)
obtained borderline scores. Chi-square analysis comparing the number of individuals with and
without alexithymia (non-alexithymic and borderline scores) in the two groups (PD and HC)
showed no statistically significant difference (Chi-square = 0.026, p = 0.871).
In addition, bivariate correlations were calculated for the four categories of subjects (PD and
HC with and without alexithymia) and the emotional and psychiatric measures administered:
Emotion Processing in Parkinson's Disease
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patients with PD and alexithymia showed a significant correlation between TAS-20 and Ekman
disgust scores, RME and Ekman total scores, RME and Ekman anger scores, and BDI and
STAI-X2 scores. Patients with PD without alexithymia showed a significant correlation between
TAS-20 and STAI-X2 scores, RME and Ekman total scores, RME and Ekman anger scores,
RME and fear scores, and BDI and STAI-X1 scores. HC with alexithymia showed a significant
correlation between RME and Ekman sadness scores, whereas HC without alexithymia showed
a significant correlation between RME and Ekman total scores, and RME and Ekman anger
scores.
In the overall group of patients with PD, as well as in the subgroups with or without alex-
ithymia, we investigated the possible correlation between emotional measures (TAS-20, RME,
Ekman 60-Faces) and, respectively, the Levodopa equivalent daily dose (Ledd) and duration of
illness. No statistically significant correlations emerged. Furthermore, in patients with PD, we
investigated the correlation between the performance on emotional measures and, respectively,
Table 1. Demographic, neuropsychological and clinical measures.
PD patients (N = 32) HC (N = 25) t-test or other statistics (specified)
Demographic variables
Age (years) 57.97 (7.20) 56.32 (6.35) 0.902 NS
Education (years) 9.47 (3.95) 10.80 (3.83) 1.279 NS
Gender—M:F 17:15 11:14 Χ2 = 0.468 NS
Neuropsychological measures
MMSE 28.78 (1.09) 29.20 (1.08) 1.467 NS
FAB 16.74 (1.30) 17.42 (0.85) 2.280 p = 0.027
Corsi’s Block-Tapping Test 4.72 (0.66) - -
Attentional Matrices 47.11 (6.74) - -
Raven Color Matrices 30.64 (3.91) - -
Bisyllabic Word Repetition Test 4.01 (0.70) - -
Paired-Associate Learning 13.24 (2.75) - -
Trail Making Test Part B 103.13 (111.15) - -
Nelson Modified Card Sorting Test - -
Categories 5.81 (0.48) - -
Errors 4.84 (3.75) - -
Perseverations 2.00 (2.07) - -
Phonemic verbal fluency 38.61 (8.10) - -
Category verbal fluency 21.28 (3.77) - -
Clinical variables 13.21 (6.11) - -
BDI 13.21 (6.11) - -
STAI-X1 44.97 (10.17) - -
STAI-X2 44.66 (8.89) - -
Apathy Evaluation Scale 13.45 (4.99) - -
Duration of illness (years) 10.56 (3.88) - -
Ledd 1075.33 (395.37) - -
UPDRS III 33.69 (9.26) - -
H&Y Off 2.81 (0.86) - -
H&Y On 1.60 (0.67) - -
BDI = Beck Depression Inventory; FAB = Frontal Assessment Battery; H&Y = Hoehn and Yahr; HC = Healthy Controls; Ledd = Levodopa equivalent daily
dose; MMSE = Mini Mental State Examination; PD = Parkinson’s Disease; STAI = State Trait Anxiety Inventory; UPDRS = Unified Parkinson’s Disease
Rating Scale.
doi:10.1371/journal.pone.0131470.t001
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the UPDRS III and the H&Y scores (indicators of severity of illness in medication-off condi-
tion), and any significance correlations emerged. Lastly, for explorative purpose, we investi-
gated the correlations between performance on the Ekman 60-Faces tests, RME, and TAS-20
(total score and subscales score) and the measures of visuospatial abilities (i.e., attentional
matrices, and Corsi’s Block-Tapping Test), the attentional matrices score correlated signifi-
cantly with RME (r = 0.551, p = 0.001), Ekman total score (r = 0.415, p = 0.020), and anger
(r = 0.431, p = 0.015), whereas Corsi’s Block-Tapping Test score correlated significantly with
disgust (r = 0.477, p = 0.007).
Discussion
Summing up, results of the present study show a specific emotion-representation deficit in the
PD sample, an overall impairment in emotion recognition, and no specific impairment in emo-
tion regulation. Patients with PD and HC were well matched in age, level of education, and
gender. Besides, they did not differ in their performance in the MMSE. Though, a significant
difference between the two groups in the FAB scores emerged, with patients performing worse
than controls. However, regarding this comparison, it is worth noting that only two patients
out of 32 got a score lower than the clinical cut-off score (i.e., 15/18), strongly suggesting that
this inter-group difference was only statistical but not clinical. Regarding emotion recognition,
patients obtained significantly worse scores than HC in the total score of Ekman 60-Faces test
but the differences in the recognition of each specific basic emotion was not significant. For
emotion representation, patients obtained significantly worse scores than HC in the RME
experimental score but no in the RME gender control task. Finally, regarding emotion regula-
tion, PD and HC did not perform differently at TAS-20 and no specific differences were found
on TAS-20 subscales. The PD impairments on emotion recognition and representation do not
correlate with dopamine therapy, disease severity, or with the duration of illness. These results
are independent from other cognitive processes, such as global cognitive status and executive
function (MMSE and FAB), or from psychiatric status such as depression, anxiety or apathy.
Table 2. Emotion processingmeasures.
PD patients (N = 32) HC (N = 25) t-test or Mann-Whitney U test
Emotion recognition
Ekman-total 43.75 (5.80) 48.12 (5.74) 2.806 p = 0.007
Ekman-sadness 6.59 (1.95) 7.42 (1.59) U = 281.5 p = 0.084 NS
Ekman-happiness 9.72 (0.73) 9.71 (0.75) U = 380.5 p = 0.928 NS
Ekman-anger 6.66 (2.19) 8.04 (1.78) U = 243.5 p = 0.018 NS
Ekman-disgust 7.84 (1.94) 8.58 (1.86) U = 284.5 p = 0.091 NS
Ekman-fear 4.25 (1.97) 5.33 (2.57) U = 277.7 p = 0.072 NS
Ekman-surprise 8.69 (1.42) 9.04 (1.16) U = 331 p = 0.357 NS
Emotion representation
RME 20.59 (5.14) 23.40 (4.65) 2.130 p = 0.038
RME control 34.09 (2.20) 35.04 (1.14) 1.950 NS
Emotion regulation
TAS 20 53.77 (10.72) 50.96 (13.28) 0.868 NS
TAS 20-F1 18.25 (6.26) 16.55 (6.61) 0.907 NS
TAS 20-F2 15.54 (4.19) 13.75 (4.74) 1.377 NS
TAS 20-F3 20.75 (5.09) 20.15 (5.39) 0.393 NS
HC = Healthy Controls; PD = Parkinson’s Disease; RME = Reading the Mind in the Eyes; TAS-20 = Twenty-item Toronto Alexithymia Scale.
doi:10.1371/journal.pone.0131470.t002
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Furthermore, as there are no statistically significant difference between patients with PD and
HC on the recognition of specific basic emotions and on the RME gender control task, we can
exclude that our results to the experimental version of the RME are due to a specific deficit in
paying attention to the eye region of the face, a possibility that can not be excluded in principle
[43–45].
Emotion recognition
To the best of our knowledge, at least five studies investigated emotion recognition level using
the Ekman 60-Faces task in a PD population [46–50]. Sprengelmeyer and colleagues [50]
showed evidence for impaired recognition of emotional facial expressions in patients with PD
than in HC. These deficits were more consistent in the non-medicated than in medicated
patients, specifically in recognising disgust and anger. A selective impairment in the recogni-
tion of anger was presented by Lawrence and colleagues [48] in a group of non-medicated
patients with PD. Treatment with dopamine replacement therapy (DRT) could mask deficits
present in PD; therefore, the study assessed facial expression recognition in a group of patients
with PD transiently withdrawn from DRT. The impairment on anger was not related to the
overall disease severity or to depression symptoms, and with relatively sparse recognition of
other emotions and facial identity processing. Different results were reported by Ibarretxe-Bil-
bao and colleagues [47], where patients with early PD obtained lower scores than HC in all
emotions except happiness, in which a ceiling-effect was observed for both PD and HC groups.
Moreover, using structural magnetic resonance to test structural changes between the groups
in the orbitofrontal cortex and amygdala, the study found grey matter loss in the orbitofrontal
cortex bilaterally and in the right amygdala, but only the former presented a strong correlation
with the performance on emotion recognition. A positive correlation between individual emo-
tion recognition and grey matter volume was found by Baggio and colleagues [46] using a
voxel-based morphometry analysis, particularly for negative emotion. Correlation was found
among the right orbitofrontal cortex, amygdala and postcentral gyrus and sadness identifica-
tion, the right occipital fusiform gyrus, ventral striatum and subgenual cortex and anger identi-
fication, and the anterior cingulate cortex and disgust identification. In the Ekman 60-Faces
task performance, PD patients presented with impaired recognition of all the negative emo-
tions assessed, whereas no differences were observed for the recognition of surprise and happi-
ness. Finally, a recent study conducted by Ricciardi and colleagues [49], that use both Ekman
60-Faces task and TAS-20, showed that patients with PD performed significantly worse than
HC in recognising surprise facial expression, with no difference in alexithymia. Interestingly,
using a dynamic expression video recording protocol, the study reported a significant
impairment in producing global facial expression in patients with PD than in HC. The results
revealed both a negative correlation between the factor F3 of TAS-20 (externally orientated
thinking) and the patient’s capability to express disgust, as well as a positive correlation
between the Ekman 60-Faces total score and the patient’s capability to express disgust.
Taking together, the studies that use the Ekman 60-Faces reported a general impairment in
emotion recognition in PD without a specific agreement on particular emotion expression
impairment. Our results are in line with these data: our PD sample obtained significantly
worse scores than HC in the total score of Ekman 60-Faces test but with no specific impairment
on any single basic emotion.
Emotion representation
Recently, an advanced view for the representational complex ability we refer to as ToM (the
general ability to represents other mental state [51–56]) has been suggested depending on the
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nature of the mental state that is represented, such as the affective ToM subcomponent, i.e.,
representation of belief about feelings, and cognitive ToM subcomponent, i.e., representation
of belief about belief [57–59]. Although cognitive ToM difficulties in PD are clearly involved in
the early clinical stages, findings on affective ToM are debatable. The spatiotemporal progres-
sion of striatal dopamine depletion in PD supports the hypothesis that this component could
be impaired in more advanced stages, when the ventromedial prefrontal cortex—found to be
involved in affective ToM—is hypostimulated by the orbital frontostriatal loop [6]. Although
the RME task is frequently used to assess emotion representation in PD, there is no agreement
in current literature as to whether or not RME performance is impaired in patients with PD,
and findings on affective ToM impairment in different clinical stages of PD are still controver-
sial [3, 6, 58].
To the best of our knowledge, only four studies showed a preserved performance on the
RME task by medicated patients in the early [60, 61] and moderate stages of PD [60, 62, 63]
with a mean disease duration from 1.69 years in Roca et al. [61], up to 10.2 years in Péron et al.
[63] (see Table 3). (Excluding severe conditions of PD, i.e. H&Y stages 4 and 5, according to
the MDS Task Force Guidelines on the Hoehn and Yahr Scale [64], clinical stages can be
defined as early on H&Y stages 1, 1.5 and 2, and moderate on H&Y stage 2.5 and 3).
A study conducted by Roca and colleagues [61] showed preserved performance on the RME
task in a group of non-medicated de novo patients with PD compared to a group of medicated
patients with PD and HC. A similar result was found by Péron and colleagues [63] investigat-
ing the effects of surgery where no differences were reported in RME task results between pre-
operative patients with PD (prior to deep brain stimulation, DBS) and HC, whereas post-oper-
ative patients with PD had lower performance than HC and pre-operative patients.
Conversely, six studies reported lower RME performances of medicated patients with PD in
comparison to HC [65–70]. Mimura and colleagues [67] reported that medicated patients at
early to moderate PD stages (Range of H&Y Stage 1–3) had poorer scores than HC on RME,
even though the authors highlighted that RME performances by both PD and HC groups were
relatively high. In a study by Tsuruya and colleagues [69], patients had a mean PD duration of
5.1 ± 0.7 years and were in early stages (H&YMean Stage 1.5 ± 0.7). Bodden and colleagues
[65] reported that patients had a mean PD duration of 5.1 ± 2.8 years but the clinical staging of
PD was heterogeneous, with both early and moderate PD (H&YMean Stage 2.5, Range 1–3).
Interestingly, Tsuruya and colleagues [69] reported an impaired performance of emotion
representation in patients with early PD; however, they performed as well as HC in the seman-
tic discrimination and gender (control) attribution tasks. Therefore, the impaired ability to
infer the emotional states of others found in patients with PD was not due to a failure in dis-
criminating emotional adjectives (semantic discrimination) or perceptual problems in visually
analysing the eye-gaze region (gender attribution).
Two recent studies seem to confirm the trend toward impairment in emotion representation
in both early and moderate PD patients [68, 70]. Using a full 36-item version of RME, Poletti
and colleagues [68] found that patients at both early and moderate PD stages (with at least
6.31 ± 4.02 years of disease duration and H&Y mean 2.08 ± 0.72) were impaired in comparison
to HC. Interestingly, patients with moderate PD had poorer RME performances than those
with early PD, but this difference did not reach statistical significance when variables correlat-
ing with RME were controlled for. Similar results were found in a very recent study that used a
34-item version of RME on patients at early PD stages [70]. Results showed that patients with
PD had a specific impairment of emotion representation in comparison to HC, at a very early
stage of PD progression (4.33 ± 5.05 years of disease duration and H&Y mean 1.97 ± 0.67).
These findings confirmed that emotion representation might be impaired in early PD.
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Our results are in agreement with these latter studies. Using a full 36-item version of RME,
we found a specific impairment on emotion representation in patients at an early to moderate
stage of PD progression, with a mean disease duration of 10.56 ± 3.88 years and mean H&Y
scores of 2.81 ± 0.86 (MED OFF). It is interesting to note that in most the previous studies [65,
68–70], the HC mean age was lower than that of the PD group (58.7 vs. 63.7 years, 66.97 vs.
68.45 years and 67.7 vs. 70.5 years, and 56.33 vs. 60.73 years, respectively). In our experimental
sample, the mean age of PD and HC groups was 57.97 and 56.32 years, respectively, with no
statistical difference between the two groups. This is particularly important, since RME perfor-
mance has been reported to decline with age in healthy subjects [71].
Converging evidence on emotion representation deficits in patients with early PD was
recently reported by Santangelo and colleagues [72] using a novel emotion attribution task to
investigate the ability to attribute emotional state to others. The authors used short stories
describing emotional situations designed to elicit attributions of sadness, fear, embarrassment,
disgust, happiness, anger, and envy, and found emotion representation impairment in patients
at very early stages of PD progression (6.8 ± 4.7 years of disease duration and H&Y mean
1.7 ± 0.6).
These results suggest that both affective and cognitive representations of the mental state
could be simultaneously impaired in early PD (see also [6]); they confirm that the deficits in
the two subcomponents of mental state representation (i.e., cognitive and affective ToM) may
be linked to dysfunction of different frontosubcortical circuitries in early stages of PD [58].
One possible explanation for the discrepancy in PD performances found on emotion repre-
sentation could be due to differences among the RME task versions used in the experimental
setting (see Table 3). Almost all the studies that found deficits in the RME, including ours,
Table 3. RME task versions used to test emotion representation in PD.
Authors Sample PD mean age in
years (SD)
Disease duration in
years (SD)
Hoen and Yahr stage RME
items
RME
performance
Euteneuer et al.,
2009
21PD/23HC 67.6 (7.3) 7.1 (6) 2.5 36/36 Preserved
Péron et al.,
2009
17 early PD/26HC 27
advanced PD/ 26HC
61.0 (7.1) 56.6
(7.8)
2.5 (1.5) 10.2 (4.9) Off 1.5 (0.7)/On 1.0 (0.9) Off
2.5 (1.0)/On 1.3 (0.9)
17/36 Preserved
Péron et al.,
2010 *
13PD/13HC 53.3 (8.5) 10.5 (3.6) Off 2.3 (0.8)/On 1.2 (0.6) 17/36 Preserved
Roca et al.,
2010 **
16PD/35HC 63.4 (8.47) 1.69 (1.55) 1.42 (0.57) 15/36 Preserved
Mimura et al.,
2006
18PD/40HC 68.9 (7.0) N/A II/III 25/36 Impaired
Bodden et al.,
2010
21PD/21 HC 63.7 (10.0) 5.1 (2.8) 2.5 (Range 1.0–3.0) 36/36 Impaired
Tsuruya et al.,
2011
20PD/20HC 70.5 (8.6) 5.1 (0.7) 1.5 (0.7) 20/36 Impaired
McKinlay et al.,
2013
50PD/49HC 66.34 (6.71) N/A 2.26 (0.82) Males 2.08 (0.84)
Females
36/36 Impaired
Poletti et al.,
2013
35PD/35HC 66.97 (11.79) 6.31 2.08 (0.72) 36/36 Impaired
Xi et al. 2014 15PD/15HC 60.73 (11.79) 4.33 (5.05) 1.97 (0.67) 34/36 Impaired
Present study 32PD/25HC 57.97 (7.20) 10.56 (3.88) On 1.6(0.67)/Off 2.81 (0.86) 36/36 Impaired
HC = Healthy Controls; PD = Parkinson’s Disease; RME = Reading the Mind in the Eyes;
* Data of preoperative patients
** Data of medicated patients
doi:10.1371/journal.pone.0131470.t003
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adopted the full 36-item version of the task [65, 66, 68] or a version with majority of the items
(25 items in Mimura et al. [67], 20 items in Tsuruya et al. [69] and 34 in Xi et al. [70]); however,
almost all studies that found preserved performance in the RME adopted a shorter version
(e.g., 17 items in Péron et al. [60, 63], and 15 items in Roca et al. [61]). Our results are in line
with Poletti et al. [68]’ suggestion: the use of a shorter version of RME instead of the complete
version could prevent detection of mild or sub-threshold impairments in affective ToM.
Emotion regulation
Different studies used the TAS-20 to test emotion regulation in PD [8–10, 73–78]. One of the
first studies that investigated emotion regulation in PD without a HC group [75], categorised
20.7% of their sample of patients with PD as alexithymic, 22.4% as borderline alexithymic, and
56.9% as non-alexithymic. They reported a strong correlation between alexithymia and severity
of depression in this population. High scores obtained on the BDI were found to strongly pre-
dict high level of alexithymia in these patients. In a further study with a HC group, Costa and
colleague [10] found that the prevalence of alexithymia was about double in patients with PD
than in the HC group: 21.4% of patients with PD and 10.0% of controls could be classified as
alexithymic, and the two groups significantly differed on global levels of alexithymia. Analyses
of individual TAS-20 subscales showed a significant difference between groups only in the dif-
ficulty in describing and communicating feelings (F2), but not in identifying feelings (F1) and
externally oriented thinking (F3). Lastly, their data showed significant associations among the
BDI, STAI, and TAS-20 factors in both groups, and confirmed the previously reported high
association between depression, anxiety, and alexithymia. A similar distribution pattern
between PD and HC with alexithymia was found by Assogna and colleagues [73], who reported
that alexithymia occurred twice as often in PD than in HC (22% vs. 11%), showing an almost
four times higher risk of having alexithymia in PD than in HC. In contrast to the previous
reports, this last study did not found a correlation between alexithymia and depression, and
reported analyses of TAS-20 subscales showing a significant difference between groups only in
the difficulty in identifying feelings (F1). The authors explained these different results based on
the difference between the HC groups: outpatients in studies by Costa and colleagues and hos-
pitalised subjects in the study by Assogna and colleagues. Finally, the authors strongly sug-
gested that alexithymia should be considered as a nonmotor symptom of PD independent of
depression. Bogdanova and Cronin-Golomb [74] found a similar dissociation between depres-
sion and alexithymia, and, in addition, between apathy and alexithymia. As expected, patients
with PD reported significantly higher levels of alexithymia than the HC group, particularly in
the difficulty in describing and communicating feelings (F2) and in externally oriented think-
ing (F3) TAS-20 subscales. In addition, these authors reported a significant association between
alexithymia and the disease stage of PD, as well as alexithymia and performance on non-ver-
bally mediated measures of executive and visuospatial function, but not on verbally mediated
tasks. Lastly, in a recent case-control study, Castelli and colleagues [8] showed an higher preva-
lence of alexithymia both in medicated PD patients (31.6%; 12/38) and in DBS PD patients
(29.6%; 8/27) than in the HC group. No significant correlation was found between TAS-20
total score and, respectively, the severity of illness and neuropsychological test scores, both for
the medicated and DBS PD patients. As far as depression is concerned, a positive correlation
was found between TAS-20 and BDI scores in the pre-DBS group but not in the DBS group.
Taken together, these findings seem to suggest that emotion regulation could be an impor-
tant cognitive and clinical symptom of PD independent of psychiatric symptoms. Specifically,
the studies that use the TAS-20 reported a general impairment in emotion regulation in PD,
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without an agreement on the selectivity and specificity of the impairment regarding the three
TAS-20 dimensions.
Our results do not confirm this conclusion. According to our data, unless the total scores
for alexithymia ranged from 34 to 70 in PD group and from 24 to 76 in HC group, the analysis
on TAS-20 total score and subscales score did not have any statistical difference between the
two groups. Nevertheless, the bivariate correlations on the four categories of subjects (PD and
HC with and without alexithymia) and the emotional levels (TAS-20, RME, and Ekman)
reported an interesting correlation between RME and Ekman scores in all the categories with
the exception of HC with alexithymia, confirming the close relation among the emotional lev-
els, in particular between emotion recognition and representation. Finally, in the overall group
of patients with PD, as well as in the subgroups of patients with or without alexithymia, no cor-
relation was found among TAS-20 scores and, respectively, dopaminergic pharmacological
treatment and duration of illness.
Depressive symptoms and visuospatial abilities
Depression is a common neuropsychiatric complication among individuals with PD [78, 79],
and it is generally accepted that clinically significant depressive disturbances occur in 40–50%
of these patients [80]. Accordingly, another crucial question in this domain is the correlation
between depressive symptom and different levels of emotion processing examined. Although
no specific correlation was found in emotion representation studies (e.g., [63, 65]), one study
on emotion recognition domain reported a significant correlation between the BDI score, and
Ekman total score and fear recognition [46]; however, a posteriori analyses showed no correla-
tion between severity of depressive symptoms and grey matter parameters in the regions where
the latter correlated with facial emotion recognition. It is important to highlight that in most
studies within this domain, the absence of depressive symptoms was an exclusion criteria and
majority of these studies were not specifically designed to test this issue.
As previously discussed, the most important correlation between emotion processing and
depressive symptom emerged in emotion regulation studies. Costa and colleagues [75]
reported that patients with PD having major depression were more alexithymic than those
who were non-depressed, and also tended to be more alexithymic than patients with minor
depression, as revealed by the overall TAS-20 score; however, no difference was found between
minor depression and non-depressed groups. High scores obtained on the BDI were found to
strongly predict high levels of alexithymia, indicating a strong association between alexithymia
and severity of depressive symptoms in PD. These effects were also obtained when partial
scores on F1 and F2 subscales were considered, although major, minor, and non-depressed
patients with PD did not differ in F3 subscale score. The authors indicated the relationship
between alexithymia and PD in general, and between depression and alexithymia in particular,
as the relevant issues in emotion processing in this population; a low association was seen
between depression and the difficulty on focusing on inner affective experience (F3). Similar
results were reported by Goerlich-Dobre and colleagues [76], with a strong correlation between
the BDI total score and TAS-20 total scores F1 and F2, but not with the F3 subscale score. Dif-
ferent conclusions were proposed by the studies that used HC control group to test this correla-
tion [10, 73, 74], where significant associations among BDI scores and TAS-20 factors were
found in both PD and HC groups. Costa and colleagues [10] showed that the correlation
between the BDI and TAS-20 scores tended to be higher among HC than patients with PD,
while in the PD group, the F2 subscale showed the lowest association with depressive symp-
toms. Both the Assogna et al. [73] and Bogdanova and Cronin-Golomb [74] studies reported a
specific association between TAS-20 total score and F1 subscale, and BDI scores equally in PD
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and HC groups. Moreover, Bogdanova and Cronin-Golomb [74] showed that the extent of
depression did not correlate with performance on neuropsychological measures of attention,
executive, and visuospatial functions. Lastly, the results of Castelli and colleagues [8] previously
described indirectly confirmed a dissociation between alexithymia and depression. The authors
found a significant correlation between alexithymia and depression only in the medicated PD
group but not in the DBS group. Accordingly, the authors suggested that depression and alex-
ithymia could be considered two distinct but partially overlapped clinical phenomena, and that
DBS of the subthalamic nucleus intervention could influence some brain circuits implicated in
depression but not in alexithymia. Taken together, these studies concluded that the specific
association between emotion regulation and PD is independent of depression, and alexithymia
in PD is not merely the expression of depressive symptoms. Our results are in accordance with
these conclusions, showing no specific correlation among emotional level and psychiatric mea-
sures, such as BDI, STAI, and Apathy Evaluation Scale.
Another important question concerning emotion processing in PD is whether visuospatial
abilities could be consider as a possible mediator between cognitive status and emotional abili-
ties in this population. This issue emerged particularly in emotion regulation studies that use
TAS-20 scale. Different authors suggest an association between alexithymia and visuospatial
processing alterations in patients with PD, supporting the view that the right hemisphere could
be specifically involved in the modulation of some facets of alexithymia [9, 74]. Patients with
PD examined by Costa and colleagues [9] displayed a neuropsychological profile mainly char-
acterised by impaired executive functions (i.e., set-maintaining and shifting) and visuospatial
abilities. Patients classified as alexithymic performed significantly worse than patients without
alexithymia, and HC with or without alexithymia, on several tasks requiring the elaboration of
visuospatial stimuli (i.e., freehand copying of drawings, and immediate visual memory). In par-
ticular, differently than in HC, where neuropsychological variables failed to predict alexithy-
mia, PD performances on a visuospatial task predicted a specific manifestation of alexithymia,
that is, F1 subscale of TAS-20. Bogdanova and Cronin-Golomb [74] showed similar results,
where alexithymia of a PD sample was associated with performance on non-verbally mediated
measures of executive and visuospatial function, but not on verbally mediated tasks.
Similar effects were found by McKinlay and colleagues [66] in emotion representation level.
Using the RME task, the authors found that the cognitive status of patients with PD was a sig-
nificant predictor for performance on the ToM task: in particular, 54% of the total effect of cog-
nitive status on ToM was mediated by visuospatial abilities. Our results partially confirm this
conclusion: we found a correlation in emotion recognition and representation levels, in partic-
ular, between disgust recognition and performance on Corsi’s Block-Tapping Test. In addition,
performance on attention matrices significantly correlated with the RME, Ekman total score,
and anger recognition.
Conclusion
PD is a common neurodegenerative condition characterised by well-known motor symptoms,
whereas the presence of cognitive non-motor symptoms, such as emotional disturbances, is
still underestimated. According to Péron and colleagues [5], PD provides a useful model for
studying the neural substrates of emotional processing, since the dopamine depletion in the
striato-thalamo-cortical circuits, like the mesolimbic dopamine system, is thought to be
involved in emotional processing. One problem emerging from studies on emotional process-
ing is the atomising approach to emotional disturbance in patients with PD, with focus of
experimental studies on one specific dimension: i.e., emotion identification, affective ToM, or
alexithymia.
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There were limitations to the present study that need to be acknowledged. Our relatively
small sample size may limit generalizability to all patients with PD, and the neuropsychological
measures used to compare PD and HC groups were limited only to MMSE and FAB. Finally,
the presence of emotional disturbances in PD remains under debate [11] and the empirical
investigation of affective dimension in PD is far to be conclusive, at least for what concerns the
influence of the disease stage in PD group selection and, more generally, for the selection crite-
ria of the healthy control group.
Despite the limitations of this study, here we addressed the question of whether people with
PD exhibit difficulties in one or more specific dimensions of emotion processing, taking into
account three different levels of analyses, that is, recognition, representation, and regulation.
Comparing these emotional levels, we found a specific deficit on the emotion representation
level, an overall impairment on emotion recognition, and no specific impairment in emotion
regulation level. The results on emotion representation, as well as the discrepancy in the perfor-
mance of patients with PD found in emotion-representation literature, could possibly result
from the RME task versions used in the experimental settings. As previously mentioned, one
important strength of the present work is the use of the full 36-item version of the RME to test
affective ToM ability. Future research should better clarify the version of RME utilised and are
encouraged to use the full version of the test in order to detect mild or sub-threshold impair-
ments in affective ToM. The use of a shorter version of RME instead of the complete 36-item
version could hamper detection of emotion-representation impairments in a neurodegenera-
tive population.
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